GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (FRA:E4NA) » Definitions » FFO per Share

Arovella Therapeutics (FRA:E4NA) FFO per Share


View and export this data going back to 2021. Start your Free Trial

What is Arovella Therapeutics FFO per Share?

FFO per Share only applies to REITs.


Arovella Therapeutics Business Description

Traded in Other Exchanges
Address
84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.